Key result
Nebivolol reduced the 12-month composite of cardiovascular events compared to metoprolol succinate (14.5% vs 31.5%, p=0.03), with no significant difference compared to carvedilol (14.5% vs 20.3%).
Why the study?
Does nebivolol or carvedilol reduce composite cardiovascular events compared to metoprolol succinate in patients with acute myocardial infarction and left ventricular dysfunction?
RCT (n=172)
Does nebivolol or carvedilol reduce composite cardiovascular events compared to metoprolol succinate in patients with acute myocardial infarction and left ventricular dysfunction?
Absolute Event Rate: 14.5% vs 31.5%
p-value: p=0.03
Nebivolol may be superior to metoprolol succinate in reducing 12-month cardiovascular events in patients with acute myocardial infarction and left ventricular dysfunction.
No takes yet. Share an insight, caveat, or question.
May support nebivolol over metoprolol; larger trials needed before practice change.
Özaydın et al. (2016) conducted an RCT in Acute myocardial infarction complicated by left ventricular dysfunction (n=172). Nebivolol vs. Carvedilol or Metoprolol succinate was evaluated on Composite of nonfatal MI, cardiovascular mortality, hospitalization due to unstable angina pectoris or heart failure, stroke or revascularization (p=0.03). Nebivolol reduced the 12-month composite of cardiovascular events compared to metoprolol succinate (14.5% vs 31.5%, p=0.03), with no significant difference compared to carvedilol (14.5% vs 20.3%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: